Financial Performance - Revenue and non-GAAP net profit increased in the first half of the year, but net profit slightly decreased due to the impact of the pandemic [2][3] - Non-recurring gains and losses decreased in the first half, but recovery began in May and is not expected to affect annual performance [2][3] Strategic Partnerships - The strategic cooperation agreement with Mengniu is expected to be renewed for another three years by the end of the year [3] - The company has partnered with Jiangzhong Pharmaceutical and Shangyao Xinyi for its probiotic business [3] Product Development and Market Strategy - The company's Jinhua Galaxy strain factory meets the production conditions for health supplements, and the company has started laying out in this area [3] - The company is focusing on both B2B and B2C markets for its probiotic business, leveraging partnerships with large food and pharmaceutical companies for B2C product development [4] - The company is conducting clinical trials and research to back the efficacy of its probiotic products [4] Operational Details - The company implements a policy of payment before delivery for its probiotic products sold through offline distributors [4] - Some R&D personnel hold shares in the company through partnerships [4] - The Beijing compound food additive factory has a designed single-shift capacity of 3,500 tons, with the ability to increase shifts to meet demand [4] Industry Insights - Developing probiotic strains requires significant investment in time and resources, and internationally recognized strains have undergone extensive research and clinical trials [3][4]

Group 1: Company Overview and Market Position - The company has been focusing on the research and development of probiotics, particularly in the area of Helicobacter pylori, which has gained significant market attention recently [2][3] - Since its establishment, the company has relied on its proprietary strain resources and has conducted over 50 clinical trials in collaboration with top-tier hospitals, with 29 trials completed [3] - The company aims to achieve technological breakthroughs and deliver products that benefit consumers and society [3] Group 2: Product Development and Clinical Trials - The company has identified several key probiotic strains, including Lactobacillus Zhang and Bifidobacterium V9, and has validated their beneficial functions through large-scale clinical trials [3] - The company has expanded into the probiotic pharmaceutical sector since 2019, elevating its research efforts [3] - The focus on Helicobacter pylori will continue, with ongoing product design and research efforts [3] Group 3: Investor Insights and Market Growth - The company believes it is on par with international probiotic companies in terms of research and development, despite starting later [3] - The domestic probiotic market is experiencing rapid growth, with significant market share still held by multinational corporations [3] - As the only publicly listed probiotic company in China, the company is confident in the future growth of its probiotic product segment [3]

Group 1: Impact of COVID-19 - The company faced challenges in logistics and customer expansion due to severe COVID-19 outbreaks in the first half of the year, although production continued at its bases in Beijing, Jinhua, and Hohhot [1] - Improvement in operations was noted starting from June [1] Group 2: Probiotic Market Overview - The overall market size for probiotic products in China was approximately 879.8 billion yuan in 2020 [1] - China has surpassed Italy to become the second-largest probiotic consumer market globally, with an annual growth rate of 11-12% [1] - The market shows significant potential for growth supported by policy and industry regulations [1] Group 3: Applications and Sales Channels - Probiotics have a wide range of applications in dairy products, healthcare, functional foods, snacks, and personal care [2] - The company has multiple proprietary brands, including "Yishiyou," "Yishenghemei," and "Baiyiduo," with "Yishiyou" being self-operated while others are authorized to distribution teams [2] - A new clinical nutrition brand "Yiyongjun" was developed and exclusively authorized to Wuhan Yongjun Biotechnology Co., Ltd. for promotion in hospitals, pharmacies, and health management institutions [2]

北京科拓恒通生物技术股份有限公司 2022 年第三季度报告 证券代码：300858 证券简称：科拓生物 公告编号：2022-072 北京科拓恒通生物技术股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 北京科拓恒通生物技术股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 107,242,551.93 ...

Financial Performance - The company reported a total revenue of RMB 300 million for the first half of 2022, representing a year-on-year increase of 15%[16]. - The net profit attributable to shareholders for the same period was RMB 50 million, up 20% compared to the previous year[16]. - The company's operating revenue for the current period is ¥156,856,172.93, a decrease of 6.25% compared to ¥167,306,738.39 in the same period last year[23]. - The net profit attributable to shareholders of the listed company is ¥44,820,865.97, reflecting a slight increase of 0.52% from ¥44,591,078.01 in the previous year[23]. - The company achieved a revenue of 156.86 million yuan in the first half of 2022, a year-on-year decrease of 6.25%[46]. - The net profit attributable to the parent company was 44.82 million yuan, reflecting a slight increase of 0.52% year-on-year[46]. - The company's total revenue for the first half of 2022 was approximately ¥156.86 million, a decrease of 6.25% compared to the same period in the previous year[74]. - The company reported a total profit of 204.5 million yuan for the first half of 2022[166]. User Engagement and Market Expansion - User data indicated a growth in active users by 25%, reaching a total of 1.5 million active users by June 30, 2022[16]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2022, driven by new product launches and market expansion[16]. - Market expansion efforts include entering two new provinces, aiming for a 30% increase in market share by the end of 2023[16]. - The company is targeting a 15% increase in export sales by entering new international markets in 2023[63]. - The company plans to expand its product line, introducing three new animal feed products by Q3 2022, targeting a 10% market share increase in the livestock sector[63]. Research and Development - The company plans to invest RMB 100 million in R&D for new product development in the next fiscal year[16]. - The R&D budget for 2023 is set at 50 million RMB, representing a 20% increase from 2022, aimed at enhancing product efficacy and safety[63]. - The company has filed for two new domestic invention patents during the reporting period, enhancing its R&D capabilities[49]. - The company is focusing on developing innovative probiotic products to meet increasing consumer demand in the health sector[16]. - The company is focusing on both B-end and C-end markets, with a differentiated marketing strategy for various channels[47]. Product Development and Innovation - The company aims to leverage its proprietary strains to replace imported probiotics, capitalizing on the unique gut microbiome of the Chinese population[37]. - The company’s plant-based microbial preparations are designed to improve soil health and enhance crop yields, addressing the growing demand for sustainable agricultural practices[43]. - The company is focused on developing probiotic strains and related technologies, aiming for long-term stable customer relationships and maximizing product sales[68]. - The company emphasizes the development of new probiotic products and formulations to meet specific consumer needs and market demands[58]. - The company is actively developing food formulas and corresponding technologies in the plant protein beverage and baked goods sectors to diversify its revenue sources[126]. Strategic Partnerships and Collaborations - The company has established deep R&D collaborations with leading enterprises in the food, pharmaceutical, and daily chemical sectors, enhancing its strategic partnerships[68]. - The company signed a strategic cooperation agreement with Mengniu Dairy for a three-year term, focusing on procurement and product supply[180]. - The company has established a partnership with Jiangzhong Pharmaceutical for the development of probiotics, with a contract signed on October 27, 2021[182]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product portfolio[182]. Market Trends and Industry Insights - The probiotics market is rapidly growing, with increasing applications in infant formula, yogurt, and beverages, indicating a trend towards expanding customer bases in the food and beverage sector[34]. - The global probiotic market is expected to grow from $61.1 billion in 2021 to $91.1 billion by 2026, at a CAGR of 8.3%[36]. - The domestic probiotic market in China was approximately ¥879.8 billion in 2020, with a growth rate of 11-12% annually[36]. - The yogurt product market in China saw a recovery in 2021, with a market size exceeding ¥1500 billion, representing a year-on-year growth of 8.6%[40]. Financial Management and Investments - The company plans to raise up to 700 million yuan through a targeted stock issuance, with 620 million yuan allocated for the food sector's R&D and production base project[50]. - The company has a commitment to produce 10,000 tons of food additives annually, with an investment of CNY 11,181,000, which is currently at 0% progress[111]. - The company has a total of CNY 32,129,100 in cumulative changes to the purpose of raised funds, indicating a significant portion of funds have been reallocated[109]. - The company has entrusted a total of 51,800 million yuan in financial management, with 30,450 million yuan currently invested[116]. Corporate Governance and Compliance - The company has established a sound internal control system and optimized its governance structure in compliance with relevant laws and regulations[152]. - The company strictly adheres to labor laws, ensuring employee rights and benefits, including contributions to social insurance[153]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[150]. - The company has implemented measures to reduce carbon emissions but did not disclose specific details[150]. Shareholder and Stock Management - The company completed the registration of 393,600 shares for the first vesting period of the 2021 restricted stock incentive plan, with the listing date on June 13, 2022[147]. - The total number of shares increased from 148,531,845 to 148,925,445, reflecting an increase of 393,600 shares due to the first vesting period of the 2021 restricted stock incentive plan[195]. - The company’s stock incentive plan was approved in board meetings held on April 24, 2022, indicating a strategic focus on employee retention and motivation[195]. - The company plans to release certain restricted shares on July 27, 2023, which may impact future shareholder dynamics[198].

Financial Performance - The company's revenue for Q1 2022 was ¥86,068,078.55, representing a 6.63% increase compared to ¥80,716,575.97 in the same period last year[3] - Net profit attributable to shareholders was ¥23,445,594.81, an increase of 8.75% from ¥21,558,322.68 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 86,068,078.55, an increase of 6.7% compared to CNY 80,716,575.97 in Q1 2021[23] - Net profit for Q1 2022 reached CNY 23,445,594.81, representing a growth of 8.8% from CNY 21,558,322.68 in Q1 2021[24] - The company achieved a total profit of CNY 28,031,886.15 in Q1 2022, compared to CNY 25,835,238.25 in Q1 2021, indicating an increase of 8.4%[24] Cash Flow - The net cash flow from operating activities reached ¥36,584,759.23, showing a significant increase of 91.43% compared to ¥19,110,813.82 in the previous year[3] - Operating cash flow for Q1 2022 was CNY 36,584,759.23, significantly higher than CNY 19,110,813.82 in Q1 2021, indicating improved cash generation[26] - Cash inflow from operating activities totaled CNY 110,404,760.68 in Q1 2022, down from CNY 125,004,472.30 in Q1 2021[26] - The net cash flow from investment activities was -236,853,601.57 CNY, compared to a positive cash flow of 99,365,015.00 CNY in the previous year[28] - The net increase in cash and cash equivalents for the quarter was -200,392,800.84 CNY, compared to an increase of 118,475,828.82 CNY in the same period last year[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,063,165,160.19, a 2.16% increase from ¥1,040,729,235.00 at the end of the previous year[3] - Total current assets were CNY 718,361,995.97, down from CNY 752,589,813.41, indicating a decrease of about 4.5%[20] - The company's accounts receivable stood at CNY 100,564,442.48, down from CNY 115,087,170.46, reflecting a decrease of approximately 12.7%[19] - Total liabilities decreased to CNY 71,015,536.93 in Q1 2022 from CNY 73,332,468.79 in Q1 2021, a reduction of 3.2%[22] - Non-current assets totaled CNY 344,803,164.22, up from CNY 288,139,421.59, showing an increase of approximately 19.6%[20] Shareholder Information - The company approved the grant of 324,000 restricted stock units to six incentive targets on January 27, 2022[17] - The total number of shares held by the top ten unrestricted shareholders includes 2,999,940 shares held by China Ping An Life Insurance Co., Ltd.[16] - The company reported a total of 95,437,413 shares under lock-up agreements as of the end of the reporting period[16] - The company plans to lift the lock-up on certain shares on July 27, 2023, affecting 62,000,000 shares held by specific shareholders[15] Other Financial Metrics - Basic earnings per share rose to ¥0.16, up 6.67% from ¥0.15 in the same quarter last year[3] - The weighted average return on equity was 2.39%, slightly up from 2.29% in the previous year[3] - Research and development expenses increased to CNY 7,635,949.69 in Q1 2022, compared to CNY 6,362,429.11 in Q1 2021, marking a rise of 20%[23] - The company reported a total of ¥3,890,686.95 in non-recurring gains and losses, primarily from government subsidies and fair value changes of financial assets[5] - Cash and cash equivalents decreased to CNY 281,430,579.21 from CNY 481,823,380.06, representing a decline of approximately 41.7%[19]

北京科拓恒通生物技术股份有限公司 2021 年年度报告全文 北京科拓恒通生物技术股份有限公司 2021 年年度报告 2022-016 2022 年 04 月 1 北京科拓恒通生物技术股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 公司负责人刘晓军、主管会计工作负责人余子英及会计机构负责人(会计主 管人员)余子英声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划等前瞻性描述不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。敬请广大投资者理性投资，注意风险。 公司可能面临的风险详见本报告"第三节 管理层讨论与分析"之"十一、公 司未来发展的展望"之"（二）公司面临的风险和应对措施"，敬请投资者关注相 关内容。 公司经本次董事会审议通过的利润分配预案为：以截至 2021 年 12 月 31 日 的总股本 ...

Financial Performance - The company's revenue for Q3 2021 was ¥100,988,785.61, a decrease of 2.64% compared to the same period last year, while year-to-date revenue increased by 10.01% to ¥268,295,524.00[3] - Net profit attributable to shareholders for Q3 2021 was ¥40,239,800.67, an increase of 18.52% year-on-year, with a year-to-date net profit of ¥84,830,878.68, up 16.95%[3] - Total revenue for Q3 2021 reached ¥268,295,524, an increase of 10.5% compared to ¥243,871,977 in Q3 2020[23] - Operating profit for Q3 2021 was ¥94,074,340, up from ¥89,505,458 in the same period last year, reflecting a growth of 6.0%[23] - Net profit for Q3 2021 was ¥84,830,878, representing a 16.9% increase from ¥72,534,281 in Q3 2020[24] Earnings and Shares - The basic earnings per share for Q3 2021 was ¥0.27, reflecting an increase of 8.00% compared to the same period last year[3] - Basic earnings per share for Q3 2021 were 0.57, down from 0.61 in the previous period[25] - The total number of shares outstanding as of the report date was 148,531,845, reflecting an 80.00% increase from the previous year-end due to capital reserve conversion[4] - The total number of common shareholders at the end of the reporting period is 10,338[10] - The largest shareholder, Sun Tiansong, holds 30.24% of shares, totaling 44,918,642 shares[10] Assets and Liabilities - Total assets at the end of Q3 2021 were ¥988,612,337.01, a decrease of 1.06% from the end of the previous year[3] - Total current assets decreased to ¥711,653,853.04 from ¥767,208,962.30, a decline of 7.3%[20] - Total non-current assets increased to ¥276,958,483.97 from ¥232,036,849.77, a growth of 19.4%[20] - Total liabilities decreased to ¥49,347,953.85 from ¥66,658,603.19, a reduction of 26.0%[21] - The company's cash and cash equivalents were ¥123,118,317.79, down from ¥202,292,031.68, a decline of 39.1%[20] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥61,530,897.19, an increase of 9.11%[3] - Cash inflow from operating activities totaled ¥334,346,992.91, an increase from ¥274,217,537.37 in the previous period, representing a growth of approximately 22%[26] - Net cash flow from operating activities was ¥61,530,897.19, compared to ¥56,393,678.63 in the previous period, indicating an increase of about 9%[26] - Cash inflow from investment activities was ¥1,093,542,173.35, significantly higher than ¥251,990,382.78 in the previous period[27] - The company reported a total cash outflow from financing activities of ¥79,596,745.85, compared to ¥9,070,000.00 in the previous period[27] Research and Development - Research and development expenses for the year-to-date period rose by 66.40% to ¥21,408,593.71, driven by increased R&D projects[8] - Research and development expenses for Q3 2021 were ¥21,408,593.71, compared to ¥12,866,028.45 in Q3 2020, an increase of 66.5%[23] Shareholder Information - The company has 61,887,692 restricted shares at the beginning of the period, with 15,960,432 shares released during the period, resulting in 95,437,413 restricted shares at the end[14] - The company adjusted the number of restricted stock grants from 820,000 to 1,476,000 shares, with the grant price reduced from 30.00 CNY to 16.11 CNY[15] - The company's registered capital increased from 82,517,692.00 CNY to 148,531,845.00 CNY after the equity distribution[16] - A total of 23,291,338 shares were released from restrictions on July 27, 2021, including 15,960,432 shares available for circulation[17] - The top ten shareholders hold significant stakes, with the second-largest shareholder holding 12.10%[10] Accounting and Reporting - The report for the third quarter was not audited, indicating preliminary figures[33] - The company is implementing new leasing standards affecting the financial statements, indicating a strategic adjustment in accounting practices[28] - The company has implemented new leasing standards effective from January 1, 2021, impacting financial reporting[33]

北京科拓恒通生物技术股份有限公司 2021 年半年度报告全文 北京科拓恒通生物技术股份有限公司 2021 年半年度报告 2021-062 2021 年 08 月 1 北京科拓恒通生物技术股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人刘晓军、主管会计工作负责人余子英及会计机构负责人(会计主 管人员)余子英声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划等前瞻性描述不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。敬请广大投资者理性投资，注意风险。公司可能面临 的风险详见本报告"第三节 管理层讨论与分析"之"十、公司面临的风险和应对 措施"，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 错误!未定义书签。 ...

Financial Performance - The company's revenue for Q1 2021 was ¥80,716,575.97, representing a 35.97% increase compared to ¥59,362,530.32 in the same period last year[7]. - Net profit attributable to shareholders was ¥21,558,322.68, up 43.07% from ¥15,068,263.54 year-on-year[7]. - Basic and diluted earnings per share increased by 8.33% to ¥0.26 from ¥0.24 in the same period last year[7]. - Total operating revenue for Q1 2021 reached CNY 80,716,575.97, compared to CNY 59,362,530.32 in the previous period, indicating a significant increase[44]. - The net profit for the first quarter reached CNY 21,558,322.68, compared to CNY 15,068,263.54 in the same period last year, representing a growth of approximately 43.3%[46]. - The operating profit for the first quarter was CNY 25,935,302.59, compared to CNY 20,359,440.53 in the previous year, reflecting a growth of approximately 27.5%[46]. - The total profit for the first quarter was CNY 25,835,238.25, compared to CNY 18,102,505.30 in the previous year, representing an increase of approximately 42.5%[46]. Cash Flow - The net cash flow from operating activities was ¥19,110,813.82, a significant improvement from a negative cash flow of ¥1,481,423.99 in the previous year, marking a 1,390.03% increase[7]. - Cash flow from operating activities was CNY 19,110,813.82, a significant increase of 1390.03% compared to a negative cash flow of CNY -1,481,423.99 in the same period last year[20]. - The cash flow from operating activities for Q1 2021 was ¥122,267,392.49, compared to ¥60,254,713.07 in the previous period, indicating a substantial increase[53]. - The cash inflow from the recovery of investments for the parent company was ¥385,324,608.59, a substantial increase from ¥26,050,060.28 in the same period last year[58]. - The company reported a total operating cash inflow of ¥125,004,472.30, which is an increase of approximately 97% from ¥63,258,584.97 in the previous year[54]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,016,465,616.03, a 1.72% increase from ¥999,245,812.07 at the end of the previous year[7]. - The total assets as of March 31, 2021, amounted to CNY 1,016,465,616.03, up from CNY 999,245,812.07 at the end of 2020[39]. - The total liabilities decreased to CNY 61,412,684.47 from CNY 66,658,603.19, showing a decline of approximately 8.5%[38]. - The company’s total liabilities increased from ¥66,658,603.19 to ¥71,479,794.01, reflecting a rise of approximately 7%[62]. - The total current assets were CNY 765,757,693.48, with cash and cash equivalents at CNY 171,936,567.89[64]. Shareholder Information - The company reported a total of 10,006 common shareholders at the end of the reporting period[11]. - The top shareholder, Sun Tiansong, holds 30.24% of the shares, totaling 24,954,801 shares[11]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12]. Research and Development - Research and development expenses rose by 86.36% to CNY 6,362,429.11, driven by increased R&D activities[18]. - Research and development expenses amounted to CNY 6,362,429.11, up from CNY 3,414,045.63, indicating a year-over-year increase of about 86.5%[46]. Government Support - The company received government subsidies amounting to ¥1,208,098.97 during the reporting period[8]. Other Financial Metrics - The total amount of raised funds is CNY 436.18 million, with CNY 2.25 million invested in the current quarter[27]. - The project for producing 30 tons of lactic acid bacteria powder and other products has achieved a completion rate of 100.02%[27]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[30]. - There were no violations of external guarantees during the reporting period[29].